FDA 483 - Catalent Belgium SA - February 07, 2026

Catalent Belgium S.A. in Brussels was inspected and cited for significant deficiencies across its drug product manufacturing operations. The inspection revealed failures in process validation, quality control procedures, adherence to written production controls, batch record completeness, and labeling accountability. These issues indicate a lack of robust control over critical manufacturing and quality systems.